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Enrofloxacin (EFX) is often used empirically to prevent uterine infections in
mares in order to improve efficiency on Commercial Embryo Transfer Farms.
This study investigated the uterine distribution of EFX and its metabolite
ciprofloxacin (CFX) in mares and assessed the minimal inhibitory concentra-
tions (MIC) of EFX against various common pathogens as a basis for establishing
a rational dosing schedule. Plasma and uterine pharmacokinetic (PK) studies
were performed in two groups (n = 5) of healthy mares following intravenous
(i.v.) administration of EFX at either 2.5 and at 5 mg ⁄ kg bodyweight. Plasma
and endometrial tissue samples, taken before for up to 48 h after treatment
were analysed by Reverse Phase HPLC. MIC values for wild strains of
Gram-negative (Escherichia coli, Pseudomonas aeruginosa) and Gram-positive
bacteria (b-haemolytic streptococci) ranged from 0.25–2 and 1.5–3.0 lg ⁄mL
respectively. In terms of tissue distribution, the sum of the endometrial
concentrations of the parent drug (EFX) and its active metabolite (CFX) (in
terms of AUC), exceeded those in plasma by 249% and 941% following
administration of EFX at 2.5 and 5 mg ⁄ kg respectively. After i.v. treatment with
EFX at 5 mg ⁄ kg, endometrial concentrations of EFX and CFX above the MIC
value were detected for 36–48 and 22–43 h posttreatment for Gram-negative
and -positive isolates respectively. Concentrations above MIC were maintained
for much shorter periods at the lower (2.5 mg ⁄ kg) treatment dose. Based on
these results, a conventional dose (5 mg ⁄ kg) of EFX given prebreeding followed
by two further doses at 36–48 h postbreeding are proposed as a rational
strategy for using of EFX as a preventative therapy against a variety of common
bacterial strains associated with equine endometritis.
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INTRODUCTION
Embryo transfer is a management technique used to facilitate
the production of foals from older breeding mares suffering
persistent chronic or non-responsive, mating-induced endome-
tritis and ⁄ or repeated early embryonic death or abortion
(Hurtgen, 2006). On Commercial Embryo Transfer Farms
(CETFs) decreasing of fertility in older mares is often a based
on their inability to eliminate the uterine fluid accumulation
after breeding, and the adherence of bacteria resulting in the
development of chronic bacterial endometritis (Watson, 2000).
Moreover, practices such as repeated examinations and
repeated breeding can lead to uterine contamination such
mares, although this problem can be alleviated by using a
meticulous preventive management programme. Several ther-
apeutic strategies have been developed to reduce the post-
breeding infection in mares susceptible to endometritis. These
include prebreeding and postbreeding uterine lavages, the
administration of oxytocin and prostaglandin to improve the
clearance of accumulated fluid and the local use of antibiotics
to prevent infections. However, the administration of treat-
ments, including ecbolic drugs, by the intrauterine route are of
limited use during diestrus. One alternative therapeutic strategy
to improve breeding efficiency in CETFs and prevent uterine
infections in mares is to administer antimicrobial drugs
intravenously.
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The normal uterus of healthy mares is usually able to
eliminate bacterial contamination and detritus introduced
during examination, breeding or foaling with a transient innate
inflammation (acute phase response) throughout the open cervix
or lymphatic drainage. However, older, multiparous mares often
require special attention and management because their innate
natural defence mechanisms are compromised with uterine
contamination in these susceptible mares often leading to
infections (Asbury et al., 1982; Blue et al., 1982; Ricketts,
1987; Brinsko et al., 1990; Causey, 2005).
The prophylactic use of antibiotics as a treatment for
endometritis, either before breeding or in semen extenders, has
long been routine practice on stud farms (Albihn et al., 2003).
Recently, the use of fluoroquinolone antibiotics has offered an
alternative to established veterinary therapy. Enrofloxacin (EFX)
(a second generation fluoroquinolone with broad spectrum
activity against Gram-negative and -positive bacteria) has been
adopted by clinical practitioners as a common empirical
treatment strategy in Argentinian CETFs. Because of its high
lipid solubility and low protein binding capacity, EFX has a large
volume of distribution, which provides high drug concentrations
in many tissues and body fluids (McKellar et al., 2004) with
tissue concentrations often being higher that concurrent serum
concentrations (Prescott & Baggot, 1994). Interestingly, empir-
ical clinical evidence indicated that pregnancy rates were higher
in susceptible healthy mares following i.v. dosing with EFX
(5 mg ⁄ kg) for 5 consecutive days. This therapeutic regimen is
identical to that used for treating severe infections and the
irrational use of EFX at such high doses for preventative purposes
could, therefore, contribute to the development of drug resis-
tance in the most common pathogenic bacteria in the uterus.
To date, there is no information on the uterine distribution of
EFX in mares, so this study was designed to investigate (i) the
relationship between the plasma disposition kinetics and endo-
metrial concentrations of EFX given intravenously at two doses
(2.5 and 5 mg ⁄ kg), (ii) assess the uterine distribution of EFX its
MIC against a range of common uterine pathogens, with the
overall purpose of proposing a rational dosing strategy.
MATERIAL AND METHODS
Determination of MIC values: microdilution antimicrobial
susceptibility tests
International Collection (ATCC, Maryland, MD, USA) and Gram-
positive and -negative field bacterial strains were used in this trial.
MIC was assessed by a microdilution method based on the
protocol established by the Clinical and Laboratory Standards
Institute (CLSI, 2006). Escherichia coli, ATCC 25922, and
Streptococcus pneumoniae, ATCC 49619 were used as quality
control strains. Clinical strains were provided by differential
culture of E. coli, Pseudomonas aeruginosa and b-haemolytic
streptococci derived from field isolates from mares suffering
endometritis. Isolates of from susceptible, but infection-free,
mares were also used to evaluate the comparative drug sensitivity
of various common pathogenic bacterial strains. Antimicrobial
working solutions were applied to microtiter plates under sterile
conditions and dried for 24–48 h at 37 C. Final drug concen-
tration ranges for EFX and CFX were 0.28–8.00 and 0.03–
1.00 lg ⁄mL for testing Gram-positive and -negative bacteria
respectively. Bacterial suspensions, equivalent to a 0.5 McFar-
land standard (1.5 · 108 CFU ⁄mL) were prepared from colonies
grown during 24 h incubations on tryptic-soy agar plates (Lab.
Britania, Buenos Aires, Argentina) for E. coli and P. aeruginosa,
and 5% sheep blood agar for b-haemolytic streptococci. The broth
microdilution method was based on a final volume of 200 lL of
Mueller Hinton broth (Lab. Britania) with a 50 lL of inoculum
of bacterial suspension diluted to a final concentration of
5 · 104 CFU ⁄mL in Mueller Hinton broth. Lysed horse blood
(5%) was also added to the broth for testing Gram-positive strains.
Microplates were sealed then incubated at 35 C before reading
after 16–20 h. The MIC was defined as the lowest antimicrobial
concentration at which, after the designated incubation period,
no visible bacterial growth was observed.
Animals, treatments and sampling
Ten cross-breeding mares (418 ± 45 kg) ranging from 12 to
16 years old, were used for this study. All the mares were
assessed to be clinically healthy after ultrasound, histological
and bacteriological examination revealed no evidence of inflam-
mation and negative bacteriological culture. Samples of plasma
and endometrial tissue biopsy were taken before treatment as
control blanks. In a parallel experimental design, the mares were
allocated into two groups (n = 5) which were treated as follows:
Group I: Mares were treated with an EFX solution (Baytril, 5%,
Bayer) by the i.v. route at 2.5 mg ⁄ kg. Group II: Mares were given
with the same EFX formulation by the same administration route
but at a higher dose of 5.0 mg ⁄ kg. Blood samples were collected
into heparinized vacutainers at 0.083, 0.25, 0.5, 1, 2, 4, 6, 12,
24, 36 and 48 h posttreatment by jugular venepuncture (using
the vein opposite to that used for EFX administration). Blood
samples were centrifuged at 2000 g for 10 min, and the
resultant plasma collected and frozen until HPLC analysis.
Endometrial tissue biopsy samples were collected at 1, 3, 6, 9,
12, 24 and 48 h post treatment. Immediately after collection
these samples were washed with saline solution water, then
wrapped in aluminium foil and kept frozen at )20 C until
analysis. All sampling procedures were approved by The Animal
Welfare Committee of The Faculty of Veterinary Medicine, http://
www.vet.unicen.edu.ar.
Chromatographic analysis for EFX and CFX
Enrofloxacin and its metabolite CFX were analysed in plasma and
endometrial tissues by Reverse Phase High Pressure Liquid
Chromatography (RP-HPLC). Chromatography was performed
on a Shimadzu (Shimadzu Corporation, Kyoto, Japan) LC system
comprising a LC-10AS liquid chromatograph pump with a
RF-10A spectrofluorometric detector, a CTO-10A VP column
oven (set at 30 C) and a Communications Bus Module-101. Data
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were collected and analysed using the Shimadzu Class LC10
software (SPD-10A; Shimadzu Corporation, Kyoto, Japan) pack-
age. Samples were injectedmanually in a 100 lL injection loop. A
Prodigy, 5 lM particle size, 250 mm · 4.6 nm C18 column
(Phenomenex, Torrance, CA, USA) was used for separation.
Plasma extracts were eluted at a flow rate of 1.2 mL ⁄min, using a
mobile phase containing 16% acetonitrile (ACN):methanol (13:1
v ⁄ v) and 84% water to which 0.4% triethylamine and 0.4%
phosphoric acid (85%) (pH 2.5 adjusted to with phosphoric acid)
were also added. For the elution of endometrial tissue extracts,
methanol was omitted from the mobile phase and the ACN
concentration was modified to 14% the ACN. All analytes were
detected by fluorescence at excitation and emission wavelengths
of 294 and 500 nm, respectively, according to the methods
described by Gonza´lez et al., 2006.
Sample preparation
Plasma
For the routine analysis of EFX and CFX, plasma aliquots (1 mL)
were placed into 5 mL glass tubes and 10 lL of marbofloxacin
(MFX) (100 lg ⁄mL) were added as internal standard (IS). Before
HPLC analysis, the analytes and IS were partially prepurified by
solid phase extraction on disposable C18 cartridges which had
been preconditioned with 0.5 mL methanol, followed by 0.5 mL
deionized ⁄ distilled water. Samples were applied to the cartridges,
whichwere thenwashedwith 3 mL deionized ⁄ distilledwater and,
after allowing as much liquid as possible to drain off, finally eluted
with 2 mL ofmethanol. Eluants were collected in 5 mL glass tubes
and evaporated to dryness under vacuum (Speed-Vac, Savant,
Los Angeles, CA, USA) at 40 C. Dried extracts were reconstituted
in mobile phase (2.4 mL) and mixed by vortexing for approxi-
mately 30 sec. Aliquots of 100 lL of the reconstituted extracts
were injected directly into the chromatographic system for
analysis. The Limit of Quantification (LOQ) for both EFX and
CFX in plasma was 0.005 lg ⁄mL as determined in the previously
published method validation (Gonza´lez et al., 2006).
Endometrial tissue
Endometrial tissue samples (150 mg) were carefully minced and
then 37.5 lL of danofloxacin (DFX, 1 lg ⁄mL) was added as IS,
followed by 350 lL phosphate buffer (pH 7). Samples were
extracted in 1 mL ACN. After stirring for 10 min at room
temperature (multi-tube vortexer), samples were centrifuged at
2500 g, for 10 min at 5 C. The resulting supernatant was
transferred into a glass tube and the extraction process was then
repeated. The supernatants from the two extractions were
combined and evaporated to dryness under vacuum as described
above for the plasma extracts. Dried extracts were reconstituted
in 1 mL methanol:phosphate buffer (pH 7.0) (20:80) and
prepurified by solid phase extraction, also as described above
for plasma with the exception that cartidges were washed with
10 volumes of deionized ⁄ distilled water before elution. The LOQ
for both analytes (again as estimated in the previously reported
method validation Gonza´lez et al., 2006) in endometrial tissue
was 0.05 lg ⁄ g.
Plasma PK analysis
Concentration vs. time curves for EFX and ⁄ or its metabolite,
CFX, in plasma and endometrial tissue for each individual
animal, after the different treatments, were fitted using com-
mercial software (PK Solution 2.0; Summit Research Services,
Ashland, OH, USA). Data points generated for the parent drug
(EFX) in plasma after i.v. administration were best fitted to a two
compartment model: Cp = Ae)k1t + Be)k2t, where A and B were
the primary and secondary disposition intercepts, respectively;
k1 and k2 were the primary and secondary disposition rate
constants (per h), respectively and Cp was the plasma concen-
tration of EFX at time t (lg ⁄mL). The distribution and
elimination half-lives were calculated as ln2 divided by the rate
constants. The estimated plasma concentration of EFX at time
zero (Cp0) after i.v. administration was the sum of the
extrapolated zero-time concentrations of the coefficients A and
B. Total body clearance (ClB) was calculated as ClB = Dose ⁄AUC.
The volume of distribution (Vdarea) was estimated by the
following equation: Vdarea = Dose ⁄ (AUC) (b). The comparative
concentration vs. time curves for the major metabolite (CFX)
were best-fitted to a biexponential equation as follows:
Cp = Be)k2t ) Be)k1t (see Notari, 1987).
Endometrial tissue PK analysis
The following equation (Notari, 1987) was used to describe
bi-exponential concentration–time curves for EFX and CFX in
endometrial tissue after the i.v. treatment:
Cp ¼ Bek2t  Bek1t
where: Cp = endometrial concentration at time t after adminis-
tration (lg ⁄mL); B = concentration at time zero extrapolated
from the elimination phase (lg ⁄ g); e = base of the natural log-
arithm; k2 = terminal slope (per h) and k1 is the slope obtained
by feathering which represents either the first order absorption
rate constant (k1) or first order metabolite formation rate con-
stant (kfor) (per h). The peak concentration (Cmax) and time to
peak concentration (Tmax) were displayed from the plotted con-
centration–time curve of each analyte. The area under the
concentration time-curve (AUC) was calculated by the trape-
zoidal rule (Gibaldi & Perrier, 1982) and further extrapolated to
infinity by dividing the last experimental concentration by the
terminal slope (k1).
Statistical analysis
Pharmacokinetic parameters and concentration data are
reported as mean ± SD. The Mann–Whitney Test was used to
compare selected PK parameters. A value of P < 0.05 was
considered statistically significant.
RESULTS
The MIC values for EFX (effectively representing the sum of
the activities of the parent drug, EFX, and its biologically
active metabolite, CFX) against Gram-negative strains (E. coli,
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P. aeruginosa) and Gram-positive (b-haemolytic) strains ranged
from 0.25–2.0 and 1.5–3.0 lg ⁄mL respectively. No adverse
effects were observed in any of the mares after the i.v.
administration of EFX at either 2.5 and 5.0 mg ⁄ kg bodyweight.
Plasma PK parameters obtained for both analytes after both
treatments are reported in Table 1. Both EFX and CFX were
detected in plasma for up to 48 h posttreatment following i.v.
administration of the parent drug (EFX) at either 2.5 and
5.0 mg ⁄ kg (Fig. 1). However, no statistical differences were
observed when the Cp0 values obtained after both treatments
were compared (Table 1). EFX and CFX plasma concentrations
correlated with the distribution of the parent drug and its
metabolite to the target tissue (endometrium) (Fig. 2). The main
parameters resulting from the endometrial PK analysis per-
formed on data for each experimental animal are summarized in
Table 2. The PK parameters obtained from the endometrial
comparison indicated that the Cmax and AUC values for both EFX
and CFX were significantly greater in the group treated with
5 mg ⁄ kg t EFX (Table 2). Relationships between the concentra-
tions of the parent drug (EFX) and its active metabolite (CFX)
detected after both treatments and the in vitro MIC’s obtained for
various bacterial isolates are illustrated in Fig. 3 and Table 3.
After i.v. treatment at 5 mg ⁄ kg, endometrial concentrations of
EFX and CFX exceeding theMIC’s for Gram-negative isolates and
the Gram-positive strains were detected in individual mares for
36–48 and 22–43 h respectively. Concentrations above MIC
were generally maintained for much shorter periods in mares
treated at 2.5 mg ⁄ kg (Table 3).
DISCUSSION
Maintenance of uterine hygiene is pivotal in avoiding
endometritis in susceptible mares and to ensure that breeding
mares are free of uterine inflammation when mating. How-
ever, current therapy of susceptible mares has focused
primarily on the postbreeding period and the removal of free
fluid and inflammatory products from the uterus. Infections
with highly pathogenic bacteria, such as those that adhere or
Table 1. Mean ± SD plasma pharmacokinetics parameters, obtained for enrofloxacin (EFX) and its active metabolite ciprofloxacin (CFX) after the
intravenous (i.v.) administration of EFX at single dose of 2.5 and 5.0 mg ⁄ kg in healthy mares
Dose
Plasma PK parameters
2.5 mg ⁄ kg 5 mg ⁄ kg
EFX CFX EFX CFX
CP0 5¢(lg ⁄mL) 6.70 ± 3.30 NA 9.60 ± 2.12 NA
Cmax (lg ⁄mL) NA 0.10 ± 0.00 NA 0.20 ± 0.10
Tmax (h) NA 1.00 ± 0.60 NA 1.60 ± 0.50
AUC(0–t) (lg h ⁄mL) 9.10 ± 2.00 0.60 ± 0.20 13.2 ± 1.90** 3.40 ± 0.40**
MRT (h) 5.90 ± 1.10 13.9 ± 6.90 23.3 ± 2.25*** 99.7 ± 26.7**
T½ k2 (h) 5.40 ± 1.30 12.8 ± 3.20 17.9 ± 6.80** 66.3 ± 21.6**
Clb (mL ⁄ h ⁄ kg) 287 ± 65.1 NA 356 ± 40.9 NA
Vd (L ⁄ kg) 1.02 ± 0.23 NA 3.81 ± 0.92** NA
NA, not applicable. **P < 0.01, ***P < 0.001.
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Fig. 1. Mean (±SD) plasma concentrations (lg ⁄mL) obtained for enro-
floxacin (EFX) and its metabolite ciprofloxacin (CFX) after the intrave-
nous administration of EFX at (a) 2.5 and (b) 5.0 mg ⁄ kg in healthy
mares.
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produce biofilms, may require antibiotic therapy (Causey,
2005). The empirical use of antimicrobials such as cephalo-
sporins, ampicillin, gentamycin and EFX by either intrauterine
or i.v. route, in endometritis-susceptible mares, is a common
practice in most intensive reproductive units. However,
irrational use of these drugs could accelerate the development
of drug resistance, and further understanding of the distribu-
tion pattern of antibiotics into the uterus is needed to develop
more rational therapeutic strategies. This study correlated the
susceptibility of bacteria most commonly isolated from mares
suffering endometritis, with the plasma PK and endometrial
distribution of the second-generation fluoroquinolone, EFX
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Fig. 2. Mean (±SD) endometrial concentrations (lg ⁄ g), obtained for
enrofloxacin (EFX) and its metabolite ciprofloxacin (CFX) after the
intravenous administration of EFX at (a) 2.5 and (b) 5.0 mg ⁄ kg in
healthy mares.
Table 2. Endometrial pharmacokinetics parameters (mean ± SD), obtained for enrofloxacin (EFX) and its active metabolite ciprofloxacin (CFX) after the
intravenous (i.v.) administration of EFX at single dose of 2.5 y 5.0 mg ⁄ kg in healthy mares
Dose
Endometrio PK parameters
2.5 mg ⁄ kg 5 mg ⁄ kg
EFX CFX EFX CFX
Cmax (lg ⁄ g) 3.90 ± 0.80 0.20 ± 0.00 7.38 ± 1.08* 0.60 ± 0.30*
Tmax (h) 1.00 ± 0.00 1.00 ± 0.00 5.00 ± 2.00 1.00 ± 0.00
AUC(0–t) (lg h ⁄ g) 29.9 ± 7.90 2.90 ± 1.80 164 ± 67* 8.90 ± 3.40*
Q. period (h) 1 to 48 1 to 24 1 to 48 1 to 36
Concentration at 48 h 0.12 ± 0.03 0.00 ± 0.00 0.96 ± 0.60** 0.00 ± 0.00
Values are statistically different to the 2.5 mg ⁄ kg group at *P < 0.05 and **P < 0.01. Q. period = period where samples were quantified above the LOQ.
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Fig. 3. Comparative endometrial total concentrations for enrofloxacin
(EFX) + ciprofloxacin (CFX) after the intravenous administration of EFX
at dose of 2.5 and 5 mg ⁄ kg in healthy mares.
Table 3. Relationship of the minimum inhibitory concentrations (MIC)
obtained for Gram-negative and -positive bacteria with the endometrial
concentrations of EFX + CFX (sum of metabolites) at the endpoint above
the MIC, after the intravenous administration of EFX at 2.5 and
5.0 mg ⁄ kg
MIC (lg ⁄mL)
Endometrio
Dose (i.v.)
(mg ⁄ kg)
Concentrations
of EFX + CFX (lg ⁄ g)
Time (h),
range
Gram-negative
0.5–2.0
5.0 2.3–0.96 36 ⁄ >48
2.5 1.3–0.5 6 ⁄ 18
Gram-positive
1.5–3.0
5.0 3.0–1.7 22 ⁄ 43
2.5 2.6–1.5 4 ⁄ 8
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and its active metabolite, CFX, in order to establish a rational
therapeutic approach for treating healthy mares to prevent
the disease and minimize selection pressure for bacterial
resistance.
To minimize the dangers of potentiating bacterial drug
resistance an essential prerequisite for this study was to
determine the susceptibility of target bacteria to the treatment
drugs. For this purpose quantitative data (MIC values) were
generated using Microdilution Antimicrobial Susceptibility Tests:
the broth microdilution method being considered the method of
choice for in-vitro susceptibility testing of bacterial pathogens
(Schwars et al., 2003; Rocksin et al., 2007). Quantitative
susceptibility varies between bacterial genera and species, as
well as between strains of a particular species. Moreover,
individual members of drug families differ quantitatively in their
antimicrobial activity (Prescott, 2000). The MIC values obtained
in this study for E.coli, P. aeruginosa and b-haemolytic strains
ranged 0.5–2.0, 0.25–2.0 and 1.5–3.0 lg ⁄mL, respectively.
Interestingly, and perhaps importantly these values were
comparable to those reported in other studies on isolates of the
same species from clinical cases of equine endometritis in other
countries (Jenkins & Friedlander, 1992; Ensink et al., 1993;
Prescott & Baggot, 1994; Bermingham et al., 2000; Haines et al.,
2000; Albihn et al., 2003).
At present no fluoroquinolones have been approved for use in
horses although interest in their use in this species is increasing
(Papich & Riviere, 2009). EFX is a second generation fluoroqu-
inolone which undergoes phase I biotransformation by a
de-ethylation reaction to form the primary metabolite, CFX.
Both EFX and CFX are biologically active and, as a consequence,
both are beneficial to the recipient. However, EFX is not
recommended for use in horses younger than 3 years old due
to secondary effects, such as degenerative damage of articular
cartilage in weight-bearing joints, of dosing growing animals.
More recently, PK studies in adult horses using both the intra-
gastric and i.v. routes have demonstrated that EFX has a suitable
PK profile, with high distribution to the target tissues in which
most the important infections are located (Gigue`re et al., 1996;
Langston et al., 1996; Kaartinen et al., 1997; Haines et al.,
2000; Papich et al., 2002; Peyrou et al., 2006). As a conse-
quence, clinical practitioners have been using EFX in adult
horses to control of infections in various tissues.
Postbreeding infections occur following either natural mating
or artificial insemination. Such infections are usually transient,
lasting <48 h, but in susceptible mares they can be sufficiently
prolonged to prevent conception (Causey, 2005). One study
demonstrated that the phagocytic activity of uterine neutrophils
was significantly lower in susceptible mares, although serum
chemotactic activity was significantly higher than in resistant
mares (Watson et al., 1987). Other studies have concluded that
uterine neutrophils from susceptible mares have significantly
lower phagocytic activity and reduced responses to chemotactic
stimuli than those from resistant mares (Cheung et al., 1985; Liu
et al., 1985). Another recent report demonstrated that, in
humans, CFX and most other fluorquinolone derivatives at
clinically achievable concentrations of >5 lg ⁄mL significantly
inhibited several pro-inflammatory cytokines (IL6, IL 1b and
TNFa) induced by lipopolisaccharides (LPS) (Riesbeck, 2006).
Similar immunomodulatory effects of CFX have also been
reported in other animal models (Riesbeck, 2002; Dalhoff,
2005). The combination of their anti-inflammatory effects and
their bactericidal activity make EFX and CPX useful candidates
for preventing endometritis in susceptible mares.
Using other analytical methods (microbiological assay and
HPLC by ultraviolet detection, respectively), Gigue`re et al. (1996)
and Papich et al. (2002), reported on preliminary studies to
assess the distribution of EFX and its active metabolite (CFX) in
the endometrium. However, the published data were insufficient
to provide a full understanding of the distribution and disap-
pearance of this molecule from endometrial tissue. In the present
study, EFX and CFX were analysed using a much more sensitive
and specific HPLC method, with fluorescence detection. This
allowed concentrations of EFX and CFX to be measured
separately, in both plasma and endometrial tissue samples, over
a period of 48 h posttreatment. The high sensitivity of method,
also allowed a detailed profile the drug depletion from the target
tissue (endometrium) to be generated. In turn, this facilitated
accurate correlations to be made between in vivo drug concen-
tration endpoints and in vitro MIC values obtained for target
bacteria. Overall, this approach has yielded data which form an
appropriate basis for the proposal of a rational dose schedule for
the prevention of infection during embryo transfer in healthy
mares.
Persistent endometritis and oviductitis lead to the loss of the
conceptus. Mares susceptible to endometritis have impaired
uterine innate defences that allow the retention of inflammatory
exudate and adherence of commensal bacteria and ⁄ or repro-
ductive pathogens to the endometrium. Treatment strategies
generally involve the use of drugs promoting contractility (e.g.
oxytocin) or anti-inflammatory steroids such as dexamethasone
although, once bacteria have adhered to the endometrium,
antibiotics should be the drugs of choice.
Consistent with other reports, mean plasma concentrations of
EFX (expressed as AUC) were significantly greater (P < 0.05)
than those obtained for CFX. Further evidence for the rapid
biotransformation of the parent drug was provided by other PK
studies, in which it was found that CFX represented approxi-
mately 20.5% of the total (i.e. EFX + CFX) plasma fluoroquino-
lone concentrations (Gigue`re et al., 1996; Papich et al., 2002)
(Fig. 1 and Table 1). Moreover, it should be noted that these
plasma CFX concentrations were sufficient to be effective
therapeutically. Interestingly, when the concentrations of the
same metabolite were assessed in the endometrium (target
tissue), the proportion of CFX was substantially less (2–8% total
EFX + CFX concentration) after mares had been treated i.v. with
either 2.5 or 5 mg ⁄ kg EFX (Fig. 2). In terms of drug distribution,
total EFX + CFX concentrations (in terms of AUCs) in endome-
trial tissue were 249% and 941% higher than the equivalent
plasma concentrations following treatment with 2.5 and
5 mg ⁄ kg EFX respectively (Tables 1 and 2). These results
confirm that the lipophilic parent drug, EFX, and its active
metabolite, CFX, are readily distributed from plasma to the
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endometrium of healthy mares, after the i.v. administration of
EFX. The latter was confirmed by comparison of the endome-
trium ⁄ plasma EFX + CFX AUC ratios which were 3.6 and 10.3
after treatment with 2.5 and 5 mg ⁄ kg EFX respectively. The
relatively higher tissue ⁄ plasma ratio after the higher dose
reported here is in contrast to values reported earlier by Papich
et al., 2002. The reasons for these differences are unclear but
may be because of factors related to breeding, reproduction cycle
(e.g. changes in uterine physiological activity) and ⁄ or the time of
season (onset or ending) when sampling was undertaken. The
extensive distribution of EFX and CFX from plasma to the target
tissue (endometrium), could explain the clinical success of using
this molecule in preventing and ⁄ or treating bacterial endo-
metritis.
Basic predictive PK and pharmacodynamic (PK ⁄ PD) values,
such as Cmax:MIC and AUC0–24:MIC, which can be used to
predict efficacy and the impact on bacterial resistance, were also
calculated from plasma concentration data obtained. However,
the parameters cited should be interpreted with caution since the
experimental design was specifically aimed at evaluating the
potential use of EFX as a preventative in the healthy uterus to
improve conception rates and avoid possible infection and
consequent inflammatory effects in susceptible mares. The
results obtained here, after dosing mares intravenously with
2.5 or 5 mg ⁄ kg EFX, showed that, for plasma, the PK ⁄ PD
surrogate markers mentioned above, did not achieve the
accepted values required to indicate efficacy against either the
Gram negatives (AUC:MIC < 125) or Gram-positive (AUC:MIC
50–60) bacteria tested respectively. The relationship between the
cited PK ⁄ PD markers was markedly lower for Gram-negative
bacteria than those reported by Papich et al., 2002. This
discrepancy appeared to be largely because of the higher (>10-
to 15-fold) MIC values obtained in this study for the wild isolates
stated rather than differences in the plasma drug concentrations
reported in both studies. However, if AUC:MIC integration was
applied to the target tissue (endometrium), using the minimum
in vitro MIC obtained, values of 340 and 680 for Gram-negative
and -positive bacteria were obtained following treatment with
5 mg ⁄ kg EFX in mares with a healthy uterus. This tissue data is
likely to be of far greater importance than the corresponding
plasma data in designing a rational therapeutic strategy.
Interestingly, fluoroquinolones appear to exhibit a ‘concentra-
tion-dependent’ activity against Gram-negative bacteria, but a
‘time-dependent’ activity against Gram-positives (Martinez et al.,
2006). The most common forms of bacterial endometritis involve
mixed infections with E. coli and b-haemolytic streptococci, of
which Streptococcus zooepidemicus has been the mostly widely
isolated species (Rogan et al., 2007). Based on these observa-
tions, the time above the MIC calculated for target tissue
(endometrium) is likely to be the best parameter on which to
base the development of a rational EFX-based therapeutic
regimen for use in embryo transfer mares.
Endometrial EFX and CFX concentrations above the MIC for
the Gram-negative and -positive isolates tested were detected
over 36–48 and 22–43 h, respectively, following i.v. treatment
at 5 mg ⁄ kg. Concentrations above MIC were maintained for
much shorter periods following treatment at 2.5 mg ⁄ kg
although there were quantitative differences between the
bacterial species tested (Table 3). Based on the results obtained
in this study, a recommended rational regime for the use of EFX
as a preventive therapeutic tool to prevent infection with either
Gram-positive and -negative bacterial strains in embryo-transfer
mares would be: 1 · dose of 5 mg ⁄ kg bodyweight intravenously
(i.v.) prebreeding and 2 · i.v. doses at 5 mg ⁄ kg 36–48 h
postbreeding.
In conclusion, the strategic use EFX by clinical practitioners,
to prevent bacterial adherence and provide effective bactericidal
concentrations in utero, in susceptible embryo-transfer mares
should facilitate improved the pregnancy rates, avoid toxicity
due to drug overdose and avoid low drug concentrations in the
uterus, which could increase the risk of development of bacterial
resistance.
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